An diesem Bord fühlt man sich als Alleinunterhalter !
Aber nichts desto trotz, hier eine Meldung, die den Kursverlauf beeinflussen wird. Ob es zur lange erwarteten Initialzündung reichen wird, da kann man allerdings nur hoffen !!!!..........
........ .......... .............................................................................................
....................................................................................... RICHMOND, Calif., Sept. 16 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. today announced that it will present at the UBS Global Life Sciences Conference in New York City on Monday, September 22, at 11:00 a.m. Eastern Time. Investors may access a live audio webcast of the presentation at http://event.streamx.us/event/default.asp?event=UBS20030922 . It is recommended that listeners log on 15 minutes early in order to register and download any necessary software.
Onyx Pharmaceuticals is engaged in the development of novel cancer therapies and has proprietary technologies that target the molecular basis of cancer. The company is developing small molecule drugs, including BAY 43-9006 jointly with Bayer Pharmaceuticals Corporation. For more information about Onyx`` pipeline and activities, visit the company``s web site at http://www.onyx-pharm.com/.
This news release contains forward-looking statements regarding expectations as to timing and amount of any restructuring charges; cost savings or clinical development expenses; the company``s plans as to the development of BAY 43-9006, including further clinical testing and the timing of such clinical trials; and the company``s expectations or beliefs of the commercial potential of BAY 43-9006. These forward-looking statements involve a number of risks and uncertainties that could cause actual events to differ from the company``s expectations. These risks are addressed in the company``s periodic reports filed with the Securities and Exchange Commission, including but not limited to its Annual Report on Form 10-K filed on March 25, 2003 and its Quarterly Reports on Form 10-Q.
Onyx Pharmaceuticals, Inc.
© PR Newswire